Clinical Trials Actively Recruiting

Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below.

Results 1 - 10 of 239

  • Objective:
    Primary Objective:
    • To compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine).
    Secondary Objectives:
    • To compare overall survival (OS) in patients randomized to N-AVD versus BV-AVD.
    • To compare event-free survival (EFS) in patients randomized to N-AVD versus BV-AVD.
    • To compare the metabolic complete response (CR) rate at the end of treatment in patients randomized to N-AVD versus BV-AVD.
    • To compare the physician-reported treatment-related adverse event rates between arms stratified by age groups.
    • To compare patient-reported symptoms using selected PRO-CTCAE items between arms stratified by age groups.
    • To compare the safety and tolerability of N-AVD versus that of BV-AVD.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Sano, Dahlia
    Karmanos Trial ID:
    • S1826
    Age Group:
    • Both
    Phase:
    • Phase III
  • Objective:
    Primary Objective:
    • To compare total bowel function score, as measured by the Memorial Sloan-Kettering Cancer Center Bowel Function Instrument (BFI), at 18 weeks post-randomization between the intervention and attention control arms.
    Cancer Categories:
    • Gastrointestinal (GI)
    Principal Investigator:
    • Tesfaye, Anteneh
    Karmanos Trial ID:
    • S1820
    Age Group:
    • Adult
    Phase:
    • Phase II
  • Objective:
    Primary Objective:
    • To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).
    Secondary Objectives:
    • To compare overall survival between the two arms.
    • To compare modified bladder intact event-free survival (mBI-EFS see Section 10) including cancer related death between arms.
    • To compare complete and partial pathologic response between arms at 3 months after completing chemoradiation therapy.
    • To estimate metastases-free survival by arm.
    • To compare the qualitative and quantitative adverse events from each arm.
    • To estimate the rate of non-muscle invasive bladder cancer recurrence by arm.
    • To estimate the rate of salvage cystectomy and reasons for cystectomy by arm.
    • To compare mean patient-reported global quality of life (QOL) at week 54 using the EORTC QLQ-C30 Global Health Status (GHS) subscale score between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with vs. without atezolizumab.
    Cancer Categories:
    • Genitourinary (GU)
    Principal Investigator:
    • Vaishampayan, Nitin
    Karmanos Trial ID:
    • S1806
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:
    Primary Objective:
    • To compare overall survival (OS) between the two treatment arms with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm in post-autologous transplant multiple myeloma (MM) patients.
    Secondary Objectives of First Randomization:
    • To compare the best overall response rate (ORR), including partial remission (PR), very good partial remission (VGPR), and complete remission (CR, sCR) in the subset of patients not in PR at randomization to lenalidomide versus lenalidomide + daratumumab/rHuPH20 in this patient population.
    • To compare progression-free survival (PFS) between the study arms in this patient population.
    • To evaluate MRD-negativity on the two treatment arms at randomization (Registration Step 2), and to compare MRD-negativity rate at 12, 24 (second randomization), 36, and 48 months after first randomization between lenalidomide and lenalidomide + daratumumab/rHuPH20 in this patient population.
    • To compare toxicities and tolerability of long term therapy between the study arms.
    Objectives of Second Randomization:
    • To compare overall survival (OS) between MRD negative patients randomized to continued lenalidomide vs. discontinued lenalidomide from the time of second randomization in this patient population.
    • To compare overall survival (OS) between MRD negative patients randomized to continued lenalidomide + daratumumab/rHuPH20 vs. discontinued lenalidomide + daratumumab/rHuPH20 from time of second randomization in this patient population.
    Cancer Categories:
    • Hematologic (Blood Cancers)
    Principal Investigator:
    • Kin, Andrew
    Karmanos Trial ID:
    • S1803
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:
    Primary Objectives
    1. To evaluate whether progression-free survival (PFS) meets an efficacy threshold in patients with previously treated advanced small bowel adenocarcinoma who receive treatment with ramucirumab and paclitaxel or FOLFIRI.
    2. If the stated threshold is met in both arms, to choose the better regimen with respect to PFS.

    Secondary Objectives
    1. To assess overall response rate (ORR) [complete and partial, confirmed and unconfirmed] in the subset of patients with measurable disease treated with ramucirumab and paclitaxel or FOLFIRI in this patient population.
    2. To assess overall survival (OS) in patients treated with ramucirumab and paclitaxel or FOLFIRI in this patient population.
    3. To evaluate safety and toxicity associated with combination ramucirumab and paclitaxel treatment or FOLFIRI therapy in this patient population.
    Cancer Categories:
    • Gastrointestinal (GI)
    Principal Investigator:
    • Shields, Anthony
    Karmanos Trial ID:
    • S1922
    Age Group:
    • Adult
    Phase:
    • Phase II
  • Objective:
    Primary Objective:
    • To evaluate the efficacy of trastuzumab and pertuzumab (TP) in HER-2 amplified metastatic colorectal cancer (mCRC) by comparing progression-free survival (PFS) on TP compared to control arm of cetuximab and irinotecan (CETIRI).
    Secondary Objectives:
    • To evaluate the overall response rate (ORR), including confirmed complete and partial response per RECIST 1.1, in the TP and CETIRI treatment arms.
    • To evaluate the overall survival (OS) in the TP and CETIRI treatment arms.
    • To evaluate the safety and toxicity of TP compared to CETIRI.
    Cancer Categories:
    • Gastrointestinal (GI)
    Principal Investigator:
    • Tesfaye, Anteneh
    Karmanos Trial ID:
    • S1613
    Age Group:
    • Adult
    Phase:
    • Phase II
  • Objective:
    Primary Objective:
    Phase II
    • To demonstrate non-inferiority in terms of progression-free survival (PFS) of concurrent reduced-dose radiation therapy (RT) with cisplatin or concurrent reduced-dose radiation therapy with nivolumab to the current standard of care (standard-dose RT with cisplatin).
    Phase III
    • To demonstrate co-primary endpoints of non-inferiority of PFS and superiority of quality of life (QOL) as measured by the MDADI of concurrent reduced-dose radiation with cisplatin or concurrent reduced-dose radiation with nivolumab to the current standard of care (standard-dose RT with cisplatin).
    Secondary Objectives:
    • To compare patterns of failure (local and regional relapse versus distant) and overall survival between each experimental arm and the control arm;
    • To assess long term PFS, overall survival, and toxicity between each experimental arm and the control arm;
    • To determine acute and late toxicity profiles as measured by the CTCAE;
    • To explore the symptomatic adverse events (AEs) for tolerability of each treatment arm as measured by the PRO-CTCAE;
    • To compare changes in patient-reported outcomes (HHIA-S, EORTC-QLQ30) between each experimental arm and the control arm;
    • To assess the association of FDG-PET/CT at baseline with locoregional control and PFS;
    • To estimate the negative predictive value of the 12-14 weeks post-RT FDG-PET/CT in terms of locoregional control rates and PFS rates at 1 and 2 years.
    Cancer Categories:
    • Head and Neck
    Principal Investigator:
    • Sukari, Ammar
    Karmanos Trial ID:
    • NRG-HN005
    Age Group:
    • Adult
    Phase:
    • Phase II/III
  • Objective:
    Primary Objectives:

    Phase II:
    • Determine the feasibility of conducting a cooperative group prospective clinical trial in patients with resected malignant salivary gland tumors;
    • Acquire preliminary efficacy data comparing postoperative radiotherapy alone to concurrent chemotherapy and radiation using weekly cisplatin.
    Phase III:
    • Compare overall survival rates among patients receiving cisplatin and radiation to those receiving radiation alone.
    Secondary Objectives:

    Phase II/III
    • Compare the acute toxicities of these 2 adjuvant treatments;
    • Compare late treatment-related adverse events in patients receiving postoperative radiation to those receiving concurrent chemoradiation;
    • Compare progression-free survival rates among patients receiving cisplatin and radiation to those receiving radiation alone in both the cohort of patients with pathologically high-risk disease (high-grade adenocarcinoma, high-grade mucoepidermoid carcinoma, salivary duct carcinoma), and the patient cohort with pathologically intermediate-risk disease (all other eligible diagnoses).
    • Investigate quality of life and patient-reported outcomes in patients enrolled in the study;
    • Identify the histopathology and tumor marker expression from patients enrolled on this trial and assemble a tissue bank for future correlative studies;
    Cancer Categories:
    • Head and Neck
    Principal Investigator:
    • Sukari, Ammar
    Karmanos Trial ID:
    • RTOG-1008
    Age Group:
    • Adult
    Phase:
    • Phase II/III
  • Objective:
    Primary:
    To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >1 cm residual invasive breast cancer and/or positive lymph nodes (>ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PDL1 positive subset.
    Secondary:
    1. To compare the effects of MK-3475 (pembrolizumab) on overall survival (OS) and distant recurrence-free survival (DRFS) between the two randomized arms for the PD-L1 positive patients and then all patients.
    2. To assess the toxicity and tolerability of MK-3475 (pembrolizumab) in this patient population with or without radiation therapy.
    Cancer Categories:
    • Breast
    Principal Investigator:
    • Flaherty, Lawrence
    Karmanos Trial ID:
    • S1418
    Age Group:
    • Adult
    Phase:
    • Phase III
  • Objective:
    Primary Objectives
    Phase II:
    • To evaluate the impact of adding LCT (local consolidative therapy) to maintenance systemic therapy versus maintenance systemic therapy alone on progression-free survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy
    Phase III:
    • To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on overall survival for patients with metastatic NSCLC with no evidence of progression and limited metastatic sites after first-line systemic therapy
    Secondary Objectives
    • To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on in-field local failure;
    • To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on the time to development of new lesions;
    • To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on toxicity;
    • To evaluate the impact of adding LCT to maintenance systemic therapy versus maintenance systemic therapy alone on duration of maintenance systemic therapy usage.
    • To evaluate the effect of adding LCT to systemic therapy in limited stage IV NSCLC on Quality of Life (QOL)
    • To collect biospecimens and evaluate the correlation between clinical outcomes and circulating tumor DNA (ctDNA)
    Cancer Categories:
    • Lung
    Principal Investigator:
    • Miller, Steven
    Karmanos Trial ID:
    • NRG-LU002
    Age Group:
    • Adult
    Phase:
    • Phase II/III